Invero Pharma believes xenon holds great promise due to its multiple mechanisms of action, extensive pre-clinical results² and positive Phase II clinical trial results which demonstrated a reduction in brain tissue damage and directionally better survival outcomes. Invero Pharma intends to become a leader in the development and commercialization of drug/device neuroprotective products that help prevent brain damage and improve mortality rates in patient populations experiencing acute injury to the brain.
¹ Laitio et. al. ,JAMA. 2016;315(11):1120-1128. doi:10.1001/jama.2016.1933
² Maze, Can J Anesth/J Can Anesth. DOI 10.1007/s12630-015-0507-8
Company Details
- Employees
- 4
- Address
- Montville, Nj, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://inveropharma.com/
- HQ
- Montville, NJ
Invero Pharma Questions
Invero Pharma's website is https://inveropharma.com/
Invero Pharma's LinkedIn profile is https://www.linkedin.com/company/invero-pharma
Invero Pharma has
4 employees.
View email and phone details for 4
employees at Invero Pharma.
Invero Pharma's industry is
Pharmaceutical Manufacturing
Invero Pharma's top competitors are
Photonamic Gmbh & Co. Kg,
Palm Therapeutics,
Millicent Pharma,
Eyecelerator,
Eydisbio, Inc.,
Enalare Therapeutics Inc.,
Neuroprotexeon,
Nx Development Corp.,
Buffalo Bio And Brews,
Datanon.
Invero Pharma's categories are Pharmaceutical Manufacturing
